Gene Therapy: Cures Within Reach
This article was originally published in Start Up
After rocky beginnings, there is increasing optimism about the potential for gene therapy to make an impact in rare disease. Promising data from late-stage clinical trials, improved safety, and the first Western regulatory approval of a gene therapy are now driving numerous initial public offerings, venture capital financings, and tie-ups with major pharmaceutical companies.
You may also be interested in...
Biotech start-ups cut deals at a rapid pace in 2015, signing almost twice the number of alliances done in 2014. Regenerative medicine was prominent in key partnerships.
Q2 biopharma financing reached $15.4 billion, a slight increase over the previous quarter; leading the M&A activity was CVS' $11.8 billion buy of Omnicare; and AstraZeneca and Juno were the two most active dealmakers in cancer immunotherapy, a popular therapeutic focus of Q2 alliances.
Reversing the “remodeling” of the heart in congestive heart failure with an investigational gene therapy is one of the aims of the San Diego-based biotech that is planning late-stage clinical development.